1. Home
  2. RGCO vs EDIT Comparison

RGCO vs EDIT Comparison

Compare RGCO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RGC Resources Inc.

RGCO

RGC Resources Inc.

N/A

Current Price

$22.74

Market Cap

233.9M

Sector

Utilities

ML Signal

N/A

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

N/A

Current Price

$2.31

Market Cap

206.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RGCO
EDIT
Founded
1912
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.9M
206.0M
IPO Year
2005
2016

Fundamental Metrics

Financial Performance
Metric
RGCO
EDIT
Price
$22.74
$2.31
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.50
AVG Volume (30 Days)
8.2K
1.4M
Earning Date
05-07-2026
06-08-2026
Dividend Yield
3.87%
N/A
EPS Growth
11.21
N/A
EPS
0.47
N/A
Revenue
$95,334,212.00
$31,937,000.00
Revenue This Year
$8.27
N/A
Revenue Next Year
$3.36
N/A
P/E Ratio
$47.96
N/A
Revenue Growth
12.63
132.64
52 Week Low
$19.68
$0.91
52 Week High
$23.82
$4.54

Technical Indicators

Market Signals
Indicator
RGCO
EDIT
Relative Strength Index (RSI) 62.21 59.89
Support Level $20.49 $2.01
Resistance Level $23.01 $2.36
Average True Range (ATR) 0.57 0.18
MACD 0.12 0.03
Stochastic Oscillator 92.89 80.01

Price Performance

Historical Comparison
RGCO
EDIT

About RGCO RGC Resources Inc.

RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: